Cargando…

Direct Left Atrial Pressure Monitoring in Severe Heart Failure: Long-Term Sensor Performance

We report the stability, accuracy, and development history of a new left atrial pressure (LAP) sensing system in ambulatory heart failure (HF) patients. A total of 84 patients with advanced HF underwent percutaneous transseptal implantation of the pressure sensor. Quarterly noninvasive calibration b...

Descripción completa

Detalles Bibliográficos
Autores principales: Troughton, Richard W., Ritzema, Jay, Eigler, Neal L., Melton, Iain C., Krum, Henry, Adamson, Philip B., Kar, Saibal, Shah, Prediman K., Whiting, James S., Heywood, J. Thomas, Rosero, Spencer, Singh, Jagmeet P., Saxon, Leslie, Matthews, Ray, Crozier, Ian G., Abraham, William T.
Formato: Texto
Lenguaje:English
Publicado: Springer US 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018612/
https://www.ncbi.nlm.nih.gov/pubmed/20945124
http://dx.doi.org/10.1007/s12265-010-9229-z
Descripción
Sumario:We report the stability, accuracy, and development history of a new left atrial pressure (LAP) sensing system in ambulatory heart failure (HF) patients. A total of 84 patients with advanced HF underwent percutaneous transseptal implantation of the pressure sensor. Quarterly noninvasive calibration by modified Valsalva maneuver was achieved in all patients, and 96.5% of calibration sessions were successful with a reproducibility of 1.2 mmHg. Absolute sensor drift was maximal after 3 months at 4.7 mmHg (95% CI, 3.2–6.2 mmHg) and remained stable through 48 months. LAP was highly correlated with simultaneous pulmonary wedge pressure at 3 and 12 months (r = 0.98, average difference of 0.8 ± 4.0 mmHg). Freedom from device failure was 95% (n = 37) at 2 years and 88% (n = 12) at 4 years. Causes of failure were identified and mitigated with 100% freedom from device failure and less severe anomalies in the last 41 consecutive patients (p = 0.005). Accurate and reliable LAP measurement using a chronic implanted monitoring system is safe and feasible in patients with advanced heart failure.